data on kras inhibitors in lung cancer at wclc 2022
Published 2 years ago • 313 plays • Length 0:35Download video MP4
Download video MP3
Similar videos
-
0:30
highlights from wclc 2022: kras-mutant lung cancer
-
0:48
targeting kras in lung cancer
-
0:47
the role of immunotherapy with kras inhibitors in kras-driven nsclc
-
1:55
highlights from the iaslc 2022 world conference on lung cancer congress
-
1:35
the role of checkpoint inhibitors in kras-mutated nsclc
-
0:31
mechanism of action of the novel krasg12c inhibitor gdc-6036
-
2:09
esmo highlights: kras g12c inhibitors
-
2:39
phase iii trial of divarasib versus adagrasib or sotorasib in kras g12c-m nsclc
-
2:38
key lung cancer updates: kras(g12c) inhibitors and adcs
-
2:31
predictive biomarkers in kras-altered nsclc treated with checkpoint inhibitors
-
2:26
targeting kras mutations in lung cancer
-
1:10
current treatment strategies krasg12c–mutated nsclc
-
1:12
overcoming resistance to kras g12c inhibitors in nsclc
-
0:58
kras g12c inhibitors for gi cancer
-
1:50
dr. parikh on kras inhibitors in lung cancer
-
1:14
impact of prior immunotherapy on hepatotoxicity with kras g12c inhibitors
-
1:09
challenges in targeting krasg12c mutations
-
2:31
how do doctors treat lung cancer with kras mutations?
-
1:10
targeting non-g12c kras mutations in nsclc